Introduction
============

Exosomes are the tiniest extracellular vesicles (EVs) involved in a complex intercellular communication system ([@B26]). EVs are categorized as exosomes due to their endocytic origin, in contrast to microvesicles that are formed from budding of the plasma membrane and apoptotic bodies derived from fragments of dying cells ([@B34]). Along with other EVs, exosomes are released by several cell types, carrying active signals that are able to influence the activity of recipient cells. Since its discovery, this extracellular communication system has been hijacked in several ways. Firstly, exosome surface markers and molecular cargoes have been worthily challenged as potential diagnostic biomarkers ([@B35]; [@B10]; [@B11]). Secondly, due to their low immunogenicity, long half-life in circulation and ability to cross the brain-blood barrier (BBB), exosomes have also been explored as a nanodelivery system of therapeutic signals, such as small interfering RNAs ([@B44]; [@B1]; [@B21]). Finally, and surprisingly, unmodified exosomes secreted by stem or progenitor cells have also shown beneficial effects and have been put forward as mediators of the regenerative responses elicited, for instance, by mesenchymal stem cells (MSCs; [@B25]; [@B57]). Indeed, the effects of these cells on tissue regeneration and repair have been mainly attributed to their secreted factors (known as secretome) rather than its *trans*-differentiation capacity ([@B49]). Having this in mind, under the scope of the present review we will address the recent evidences of the regenerative potential of MSCs-derived exosomes into different pathological conditions.

Exosomes As Cell-Secreted EVs
=============================

Exosomes and microvesicles are the most thoroughly studied classes of EVs. Both are membrane-enclosed vesicles, surrounded by a phospholipid layer and packed with cell-type specific combinations of proteins, lipids, coding, and non-coding RNAs ([@B29]). Once released into the extracellular milieu, EVs can be taken up by target cells of the microenvironment or carried to distant sites through biological fluids, from which they have already been isolated, including urine ([@B41]), breast milk ([@B66]), blood ([@B6]), and cerebrospinal fluid ([@B43]).

In spite of their relative availability, the complexity of the extracellular environment and the existence of extracellular RNA in other non-EV carriers, such as protein complexes and lipoproteins, has encouraged the International Society for Extracellular Vesicles (ISEV; [@B32]) to establish minimal requirements for describing EVs, namely: (i) isolation from extracellular body fluids or conditioned cell culture medium, with minimal cell disruption; (ii) quantification of at least one protein from three different categories (transmembrane or lipid bound extracellular proteins, cytosolic proteins and intracellular proteins) in the EV preparation; (iii) characterization of single vesicles within the EV preparation using at least two different technologies, electron microscopy or atomic force microscopy (AFM) for imaging and nanoparticle-tracking analysis, dynamic light scattering, or resistive pulse sensing for size distribution measurements of EVs ([@B32]). EVs are further classified as exosomes or microvesicles based on their intracellular biogenesis pathway. Microvesicles are originated at the cell surface and released by direct outward budding of the plasma membrane, whereas exosomes are formed within multivesicular bodies (MVBs) at the endolysosomal pathway and secreted upon fusion of MVBs with the plasma membrane (**Figure [1A](#F1){ref-type="fig"}**; [@B21]).

![**Origin, composition, and therapeutic potential of MSCs-derived exosomes. (A)** Endocytic origin of MSCs-derived exosomes and influence of tissue from which MSCs are isolated and culture conditions on exosome secretion profile. **(B)** Size and composition of exosomes, depicting in gray the molecular markers of exosomes (CD9, 63, 81, and 82, ALIX and TSG10). **(C)** Therapeutic potential and suggested miRNAs and proteins mediating the regenerative effects of MSCs-derived exosomes. MSCs, mesenchymal stem cells; RER, rough endoplasmic reticulum; GC, Golgi complex; MVBs, multivesicular bodies; NEP, Neprilysin; ESC, embryonic stem cells; iPSCs, induced pluripotent stem cells.](fphar-07-00231-g001){#F1}

Exosomes comprise a homogenous population of nano-sized vesicles, as their diameter ranges from 30 to 150 nm ([@B29]; [@B55]). Additionally, exosomes are also a better characterized population of EVs. Exosomal proteins, RNAs and lipids described in published and unpublished studies have been cataloged in ExoCarta, a database that aims to identify specific molecular signatures of tissue/cell-type derived exosomes ([@B33]). ALIX and TSG10 have been recognized as common protein markers for exosome identification, due to their participation in the endosomal sorting complex required for transport (ESCRT), as well as membrane proteins of the tetraspanin family, such as CD9, CD63, CD81, CD82 (**Figure [1B](#F1){ref-type="fig"}**; [@B56]; [@B17]).

Conventional methods for isolation of exosomes include ultracentrifugation, density gradient separation, chromatography and immunoaffinity capture (IAC) techniques as well as commercial kits, such as polymer-based precipitation. Despite being all capable to isolate vesicles with exosomal diameter and markers, some authors have suggested IAC as the most effective method to isolate exosomes, based on the number of exosome-related proteins identified on the purified fraction ([@B47]; [@B14]). However, there is an ongoing debate on the ability of these methods to fully separate exosomes from protein aggregates and other membranous vesicles. The distinction between microvesicles and exosomes, for instance, is challenging as a result of the heterogeneity of microvesicles diameter (50--1000 nm), as well as small amount of protein markers to clearly categorize EVs produced via budding from the cell membrane or produced via endosomal compartment. Therefore, the ISEV ([@B32]) has recommended cautious interpretation of some exosomal-mediated responses described so far. In fact, some studies focused on the evaluation of the individual contribution of exosomes and microvesicles, report unique effects of exosomes- and microvesicles- enriched fractions that were obtained through differential centrifugation steps ([@B19]; [@B31]). Even within the same population of exosomes, [@B55] have defined two distinct subpopulations of exosomes based on distinct particles sizes that enclose different protein and RNA compositions and, therefore, yield different effects on recipient cells. Taken together, these studies show that the improvement of current isolation methods and a better understanding of exosomal biology are of key importance to clearly determine the therapeutic effects of exosomes.

MSCs and MSCs-Derived Exosomes
==============================

The regenerative potential of MSCs and particularly of their secretome has been extensively reviewed ([@B49]; [@B42]; [@B24]). MSCs are a population of adult multipotent cells with the ability to self-renew and differentiate into mesenchymal lineages, namely osteoblasts, chondrocytes, and adipocytes ([@B39]). Even though originally isolated from bone marrow (BM-MSCs; [@B13]), MSCs have been successfully identified and isolated from other adult tissues, such as adipose tissue (ASCs), dental pulp, placenta, amniotic fluid, umbilical cord blood, umbilical cord Wharton's jelly (WJ-MSCs) and its perivascular region (HUCPVCs), and even the brain ([@B49]). MSCs differentiation potential has been explored in cell replacement strategies aiming to restore compromised adult mesenchymal tissues, although some authors have also reported its differentiation into ectodermal lineages ([@B9]; [@B45]; [@B4]). Nonetheless, the paradigm of MSCs-mediated regeneration has been shifting toward a secretome-based paracrine activity, rather than its cellular engraftment and differentiation. Indeed, it has been widely accepted that MSCs secrete bioactive factors with strong immunomodulatory activities, which are also able to inhibit fibrosis and apoptosis, enhance angiogenesis and promote neuronal survival and differentiation ([@B8]; [@B48]). As a result, the use of MSCs conditioned medium (CM) has been put forward as a cell-free strategy with promising therapeutic effects, including reduction of myocardial infarct size ([@B51]), trophic support to injured liver ([@B53]) and protective effects on acute kidney injury ([@B60]).

Initial studies from [@B51] on ischemia and reperfusion injury, demonstrated that only the fraction of the CM containing products \> 1000 kDa provided cardioprotection. At that time, the authors suggested the existence of a complex of proteins and lipids (with a predicted diameter of 50--100 nm) mediating MSCs paracrine activity. Three years later, the same group ([@B25]) isolated and characterized exosomes from human ESC-derived MSCs CM, for the first time. These spherical structures were readily visualized at the CM by electron microscopy, and further precipitated by ultracentrifugation. The presence of exosomes was also evidenced by the enrichment in plasma membrane phospholipids, such as cholesterol, sphingomyelin and phosphatidylcholine, as well as coprecipitation of exosome-associated proteins, including CD81, CD9, and ALIX. Thenceforward, a novel perspective of intercellular mediation of tissue repair was highlighted.

Enclosed RNA molecules have been described as the main messengers of the responses induced by exosomes. Indeed, coding mRNA molecules packed within exosomes are functionally translated at recipient cells ([@B52]). Notwithstanding, small non-coding RNAs (20--30 nucleotides), and particularly microRNAs (miRNA), have been described as major mediators of cell--cell communication as they are able to regulate gene expression via miRNA degradation and repression of translation ([@B15]). A small RNA profiling of BM-MSCs and ASCs exosomes, recently performed by [@B5], revealed that, along with miRNA, MSCs exosomes are highly enriched in transfer RNA (tRNA) species that can function as miRNAs. Furthermore, while cellular small RNA expression profile is not donor- or tissue-specific, exosomal small RNA content seems to be greatly influenced by cell differentiation status, i.e., donor variability, and cell type ([@B5]). The authors suggest that exosomal-enclosed small RNAs released by MSCs may distinctly control the microenvironment in their resident niches through a balance between proliferation and differentiation ([@B5]). This study shed light on possible regulatory mechanisms of MSCs paracrine activity responsible for tissue-specific MSCs CM regenerative properties that were previously described by our laboratory ([@B40]). Recently, tissue-specific responses were also described for exosomes isolated from different sources. For instance, ASCs-derived exosomes seem to be more effective in degrading Aβ in an *in vitro* model of Alzheimer's disease (AD), when compared to BM-MSCs-derived exosomes ([@B22]), whereas neurite outgrowth response appears to be enhanced by exosomes released by menstrual fluid derived MSCs, when compared to umbilical cord, chorion and bone marrow ([@B31]). These studies unveil the need to further distinguish the functional properties of exosomes released by MSCs isolated from different adult tissues to better understand their individual regenerative potential. The influence of gender on MSCs exosomal secretion profile should be also taken into account in future studies.

MSCs-Derived Exosomes Applied to Tissue Regeneration
====================================================

Since the report of MSCs-derived exosomes, a growing amount of studies have explored their regenerative potential using different *in vitro* and *in vivo* models (**Figure [1C](#F1){ref-type="fig"}**). In the present report we will focus on those that, in our opinion, are the most relevant.

Cardiovascular System
---------------------

MSCs-derived exosomes were firstly suggested as cardioprotective agents by Kleijn's group ([@B25]). Subsequently, other studies have addressed the proangiogenic effects of MSCs exosomes as a mechanism of tissue repair upon ischemia. [@B7] firstly showed that MSCs secrete a large quantity of exosomes under hypoxia and serum deprivation. In a similar ischemic conditioning, MSCs were shown to secrete exosomes enriched with miR-22, which led to the reduction of apoptosis and cardiac fibrosis through a direct targeting of methyl CpG binding protein 2 (Mecp2; [@B12]). In line with this, a recent analysis of the proteomic profile of MSCs-derived exosomes cultured under these conditions revealed a robust profile of angiogenic signaling proteins, including NFkB interacting proteins, which mediate tubule formation upon low to medium doses (1--10 μg/mL) treatment of MSCs-derived exosomes ([@B2]).

Importantly, several authors have demonstrated that internalization of MSCs-derived exosomes by endothelial cells stimulate proliferation, migration and tube formation (*in vitro*) and promote angiogenesis when injected intramyocardially in acute myocardial infarction rat models ([@B7]; [@B50]). [@B16] have also evidenced that intramuscular injection of exosomes secreted by human induced pluripotent stem cells-derived MSCs (iPSCs-derived MSCs) promote endothelial cell migration, proliferation, and tube formation through the activation of angiogenesis-related molecule expression (VEGF, TGFB1, and Angiogenin), leading to an increase of microvessel density and blood perfusion in a mouse hind-limb ischemic model.

In a follow-up study, [@B3] have shown that a single intravenous administration of exosomes was effective in enhancing cardiac function and geometry after myocardial infarction due to bioenergetics reestablishment (increased ATP production), oxidative stress reduction and pro-survival signaling activation (enhanced PI3K/Akt signaling). A similar outcome was presented by [@B54] in polymicrobial sepsis.

Asahara's group ([@B64]) have used the proliferative and angiogenic potential of MSCs exosomes to condition cardiac stem cells (CSC) *in vitro*, which when transplanted into a rat model of myocardial infarction were able to preserve cardiac function.

Kidney
------

Acute kidney injury has also been effectively treated with MSCs exosomes. *In vitro*, treated renal tubular epithelial cells exhibited increased activation of extracellular-signal-regulated kinase (ERK)1/2 pathway and thus increased cell proliferation ([@B65]). *In vivo*, after direct injection into injured kidneys (cisplatin-induced acute kidney injury rat model), hucMSCs-Ex were shown to be incorporated into the tubular epithelial cells and to promote functional and morphologic recovery by reducing oxidative stress and suppressing apoptosis ([@B65]). Recently, [@B20], characterized urine-derived stem cells as multipotent MSCs (USCs) and a source of exosomes, and demonstrated that when intravenously injected they were able to reduce kidney deficits in type I diabetic rats.

Liver
-----

HucMSCs-Ex have also been explored as a treatment to fibrotic liver disease, which can be induced by viral hepatitis, alcohol, drugs, metabolic diseases, and autoimmune attack of hepatic cells ([@B30]). [@B30], have demonstrated that after liver fibrosis \[induced by carbon tetrachloride (CCl4)\], the delivery of exosomes into the liver reduced fibrosis through the inactivation of the transforming growth factor (TGF)-β 1/Smad signaling pathway, as well as through the inhibition of epithelial-to-mesenchymal transition of hepatocytes. Using the same mouse model, [@B18] demonstrated that chorionic plate-derived MSCs retained miR-125b in exosomes which suppressed the Hedgehog activation and consequently liver fibrosis. In addition to this, the hepatic regenerative potential of hESC-derived MSCs exosomes was also evidenced using two *in vitro* models of liver injury \[acetaminophen (APAP)- and (2) hydrogen peroxide (H~2~O~2~)\], in which treatment resulted in increased anti-apoptotic and proliferative responses ([@B46]).

Immune System
-------------

In accordance to well-known MSCs immunomodulatory effects, MSCs exosomes have also been described as immunological active agents as they induce high levels of anti-inflammatory cytokines, in contrast to decreased levels of pro-inflammatory molecules, providing a rationale for the use of exosomes for the treatment of immune disorders ([@B61]). In addition, MSCs exosomes can also inhibit macrophage activation by suppressing Toll-like receptor signaling, providing a physiologically relevant context for the innate immunomodulatory activity of MSCs ([@B38]). In a mouse model of hypoxic pulmonary hypertension, [@B27] demonstrated that the intravenous delivery of exosomes derived from MSCs CM suppress hypoxic inflammation by inhibition of pro-proliferative pathways, such as STAT3 phosphorylation.

Musculoskeletal System
----------------------

In the context of bone regeneration, [@B37] demonstrated the potential of exosomes released by MSCs cultured under osteogenic conditions. In a 2D and in a 3D (type I collagen hydrogels) culture these exosomes triggered osteogenic differentiation of undifferentiated MSCs. *In vivo*, when implanted subcutaneously in a grade collagen membrane, "osteogenic" exosomes promoted calcium deposition and calcium phosphate nucleation. In addition, [@B36] have also suggested that MSCs-derived exosomes are able to promote skeletal muscle regeneration by enhancing myogenesis and angiogenesis and have considered exosome-enclosed miR-494 an important mediator of this response.

Nervous System
--------------

MSCs-secretome has shown therapeutic benefits for the treatment of neurological and neurodegenerative diseases. Accordingly, [@B57], [@B59]) have demonstrated that miR-133b, increased in MSCs exposed to ischemic cerebral extracts, is transferred to neurons and astrocytes via exosomes and promotes neurite outgrowth and functional recovery in a middle cerebral artery occlusion model. In another study, these authors ([@B58]) demonstrated that after stroke, the intravenous administration of cell-free MSCs-generated exosomes also enhances neurite remodeling, neurogenesis and angiogenesis and therefore, improves functional recovery. Similar encouraging outcomes were obtained in a traumatic brain injury model, in which intravenous administration of MSCs-generated exosomes enhanced angiogenesis and neurogenesis, reduced inflammation and improved spatial learning and sensimotor function ([@B63]; [@B23]).

[@B22] have provided an important role for ASCs-derived exosomes in the context of AD, as these express high levels of Neprilysin (NEP), the most important Aβ-degrading enzyme in the brain. NEP-loaded exosomes were shown to be efficiently transferred to neuroblastoma cells and led to the decrease of both extracellular and intracellular Aβ levels. In another *in vitro* neurodegeneration model, exosomes released by dental pulp-derived MSCs on a 3D culture, rescued dopaminergic neurons from 6-OHDA induced apoptosis, thereby providing a possible treatment of Parkinson's disease ([@B19]).

Other studies have focused on non-diseased *in vitro* models to demonstrate MSCs-derived exosomes potential for neuronal differentiation. For instance, [@B28] reported that BM-MSCs deliver miR-124 and miR-145 to human neural progenitor cells (NPCs) and astrocytes via contact independent and exosome-dependent processes, which alter gene expression in the recipient neural cells. Indeed, exosomal-mediated axonal growth seems to depend on argonaut 2 protein, a miRNA machinery protein, whereas internalization of BM-MSCs exosomes in cell bodies and axons has been suggested to occur via SNARE complex ([@B62]). [@B31] have recently unraveled the potential of menstrual MSCs (MenSCs) exosomal-enriched fraction as therapeutic approach in neurodegenerative pathologies. These authors demonstrated that MenSC exosomes induced neurite growth in cortical neurons and had a similar effect to BM-SC exosomes on neurite outgrowth of dorsal root ganglia neurons.

Conclusion and Future Perspectives
==================================

MSCs-derived exosomes have emerged, in the last six years, as an attractive and safe approach for regenerative medicine applications. Of note, the intravenous administration of these nanovesicles has not elicited adverse effects. In addition, MSCs-derived exosomes regenerative effects reinforce the paradigm of secretome-based paracrine action of MSCs and support future perspectives for the development of cell-free therapies that avoid the safety concerns associated to stem cell transplantation and are less technically difficult to prepare and deliver. Nevertheless, this is a still developing research area that needs to be optimized to take full advantage of MSCs-derived exosomes regenerative potential. For instance, the choice of MSCs source and their culture conditions must be explored, as these have been shown to impact the functional properties of the exosomes.
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